These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 36397383)

  • 21. Comparative effectiveness of second-line biological therapies for ulcerative colitis and Crohn's disease in patients with prior failure of anti-tumour necrosis factor treatment.
    Hyun HK; Zhang HS; Yu J; Kang EA; Park J; Park SJ; Park JJ; Kim TI; Kim WH; Cheon JH
    BMC Gastroenterol; 2022 Mar; 22(1):143. PubMed ID: 35346063
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Refractory case of ulcerative colitis with idiopathic thrombocytopenic purpura successfully treated by Janus kinase inhibitor tofacitinib: A case report.
    Komeda Y; Sakurai T; Sakai K; Morita Y; Hashimoto A; Nagai T; Hagiwara S; Matsumura I; Nishio K; Kudo M
    World J Clin Cases; 2020 Dec; 8(24):6389-6395. PubMed ID: 33392322
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dual Biologic and Small Molecule Therapy for the Treatment of Refractory Pediatric Inflammatory Bowel Disease.
    Dolinger MT; Spencer EA; Lai J; Dunkin D; Dubinsky MC
    Inflamm Bowel Dis; 2021 Jul; 27(8):1210-1214. PubMed ID: 33125058
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical outcomes with ustekinumab as rescue treatment in therapy-refractory or therapy-intolerant ulcerative colitis.
    Ochsenkühn T; Tillack C; Szokodi D; Janelidze S; Schnitzler F
    United European Gastroenterol J; 2020 Feb; 8(1):91-98. PubMed ID: 32213052
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy and safety of biologics and small molecule drugs for patients with moderate-to-severe ulcerative colitis: a systematic review and network meta-analysis.
    Lasa JS; Olivera PA; Danese S; Peyrin-Biroulet L
    Lancet Gastroenterol Hepatol; 2022 Feb; 7(2):161-170. PubMed ID: 34856198
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Tofacitinib in the treatment of moderate to severe ulcerative colitis in Colombia: Real world experience.
    Parra-Izquierdo V; Frías-Ordoñez JS; Márquez JR; Juliao-Baños F; Galindo P; Cuadros C; Rojas C; Rojas N; Ardila O; Tovar-Fierro G; García-Duperly R; Vargas M; Flórez-Sarmiento C
    Gastroenterol Hepatol; 2023; 46(7):512-521. PubMed ID: 36372256
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Real-world Effectiveness of Tofacitinib for Moderate to Severe Ulcerative Colitis: A Multicentre UK Experience.
    Honap S; Chee D; Chapman TP; Patel M; Kent AJ; Ray S; Sharma E; Kennedy J; Cripps S; Walsh A; Goodhand JR; Ahmad T; Satsangi J; Irving PM; Kennedy NA;
    J Crohns Colitis; 2020 Oct; 14(10):1385-1393. PubMed ID: 32280965
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Integrating efficacy and safety of vedolizumab compared with other advanced therapies to assess net clinical benefit of ulcerative colitis treatments: a network meta-analysis.
    Jairath V; Chan K; Lasch K; Keeping S; Agboton C; Blake A; Patel H
    Expert Rev Gastroenterol Hepatol; 2021 Jun; 15(6):711-722. PubMed ID: 33599181
    [No Abstract]   [Full Text] [Related]  

  • 29. Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis.
    Sandborn WJ; Su C; Sands BE; D'Haens GR; Vermeire S; Schreiber S; Danese S; Feagan BG; Reinisch W; Niezychowski W; Friedman G; Lawendy N; Yu D; Woodworth D; Mukherjee A; Zhang H; Healey P; Panés J;
    N Engl J Med; 2017 May; 376(18):1723-1736. PubMed ID: 28467869
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Randomized trial of tofacitinib in active ulcerative colitis: analysis of efficacy based on patient-reported outcomes.
    Panés J; Su C; Bushmakin AG; Cappelleri JC; Mamolo C; Healey P
    BMC Gastroenterol; 2015 Feb; 15():14. PubMed ID: 25651782
    [TBL] [Abstract][Full Text] [Related]  

  • 31. First- and Second-Line Pharmacotherapies for Patients With Moderate to Severely Active Ulcerative Colitis: An Updated Network Meta-Analysis.
    Singh S; Murad MH; Fumery M; Dulai PS; Sandborn WJ
    Clin Gastroenterol Hepatol; 2020 Sep; 18(10):2179-2191.e6. PubMed ID: 31945470
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Characterization of Creatine Kinase Levels in Tofacitinib-Treated Patients with Ulcerative Colitis: Results from Clinical Trials.
    Panaccione R; Isaacs JD; Chen LA; Wang W; Marren A; Kwok K; Wang L; Chan G; Su C
    Dig Dis Sci; 2021 Aug; 66(8):2732-2743. PubMed ID: 32816215
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy and Safety of Extended Induction With Tofacitinib for the Treatment of Ulcerative Colitis.
    Sandborn WJ; Peyrin-Biroulet L; Quirk D; Wang W; Nduaka CI; Mukherjee A; Su C; Sands BE
    Clin Gastroenterol Hepatol; 2022 Aug; 20(8):1821-1830.e3. PubMed ID: 33127596
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evaluating cost per remission and cost of serious adverse events of advanced therapies for ulcerative colitis.
    Jairath V; Cohen RD; Loftus EV; Candela N; Lasch K; Schultz BG
    BMC Gastroenterol; 2022 Dec; 22(1):501. PubMed ID: 36474165
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The impact of body mass index on efficacy and safety in the tofacitinib OCTAVE ulcerative colitis clinical programme.
    Farraye FA; Qazi T; Kotze PG; Moore GT; Mundayat R; Lawendy N; Sharma PP; Judd DT
    Aliment Pharmacol Ther; 2021 Aug; 54(4):429-440. PubMed ID: 34165201
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cytapheresis re-induces high-rate steroid-free remission in patients with steroid-dependent and steroid-refractory ulcerative colitis.
    Iizuka M; Etou T; Shimodaira Y; Hatakeyama T; Sagara S
    World J Gastroenterol; 2021 Mar; 27(12):1194-1212. PubMed ID: 33828394
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Maintenance of Remission With Tofacitinib Therapy in Patients With Ulcerative Colitis.
    Colombel JF; Osterman MT; Thorpe AJ; Salese L; Nduaka CI; Zhang H; Lawendy N; Friedman GS; Quirk D; Su C; Reinisch W
    Clin Gastroenterol Hepatol; 2022 Jan; 20(1):116-125.e5. PubMed ID: 33039585
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Real-world characteristics, treatment experiences and corticosteroid utilisation of patients treated with tofacitinib for moderate to severe ulcerative colitis.
    Chiorean MV; Allegretti JR; Sharma PP; Chastek B; Salese L; Bell EJ; Peterson-Brandt J; Cappelleri JC; Guo X; Khan N
    BMC Gastroenterol; 2022 Apr; 22(1):177. PubMed ID: 35397501
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis.
    Sandborn WJ; Ghosh S; Panes J; Vranic I; Su C; Rousell S; Niezychowski W;
    N Engl J Med; 2012 Aug; 367(7):616-24. PubMed ID: 22894574
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy and safety of tofacitinib dose de-escalation and dose escalation for patients with ulcerative colitis: results from OCTAVE Open.
    Sands BE; Armuzzi A; Marshall JK; Lindsay JO; Sandborn WJ; Danese S; Panés J; Bressler B; Colombel JF; Lawendy N; Maller E; Zhang H; Chan G; Salese L; Tsilkos K; Marren A; Su C
    Aliment Pharmacol Ther; 2020 Jan; 51(2):271-280. PubMed ID: 31660640
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.